The expression of the transmembrane glycoprotein CD38 is well documented in hematological cancers, including multiple myeloma (MM), certain types of lymphoma, and leukemia; the prevalence and expression level of CD38 is lower and more variable in non‐MM cancers.2, 9, 10, 11, 12, 13, 14. This evidence concerns the gene CD38 and AL amyloidosis.